BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Medtronic, Inc. (MDT) Completes Acquisition of Ablation Frontiers


2/6/2009 9:22:48 AM

MINNEAPOLIS & CARLSBAD, Calif.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today announced it has through an affiliated entity, completed the acquisition of privately held Ablation Frontiers, Inc. Under the terms of the agreement announced Jan. 12, 2009, the transaction includes an initial payment of $225 million plus potential additional payments contingent upon achievement of certain clinical milestones.

Operating within Medtronic’s Cardiac Rhythm Disease Management (CRDM) business, Ablation Frontiers and the recently acquired CryoCath Technologies, Inc., expand the company’s recently launched AF Solutions business. Medtronic’s goal is to be the physician partner of choice for atrial fibrillation (AF) ablation by bringing breakthrough AF therapies to patients and physicians that are simpler, safer, effective, and offer more predictable procedure times than current treatment methods.

About Ablation Frontiers

Ablation Frontiers, Inc. (www.ablationfrontiers.com) is a medical device company based in Carlsbad, Calif., dedicated to helping individuals suffering from AF and other cardiac arrhythmias. In 2006, Ablation Frontiers received CE Mark to begin marketing its system of catheters and the GENius™ Radiofrequency (RF) Generator in the European Union to treat supraventricular arrhythmias and for use in atrioventricular node ablation. Ablation Frontiers is conducting a clinical trial under a United States Food and Drug Administration (FDA) investigational device exemption (IDE) to gain approval of the catheter system for permanent/long-standing persistent/chronic AF in the United States. Ablation Frontiers products are not approved for marketing or sales in the United States.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology ? alleviating pain, restoring health, and extending life for millions of people around the world.

This press release contains forward-looking statements regarding our operating momentum, new products and other developments, which are subject to risks and uncertainties, such as competitive factors, the risk that Ablation Frontiers may not be integrated successfully and that the cost savings and other synergies from the acquisition may not be fully realized, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, general economic conditions and other risk and uncertainties described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements.

Contact:

Medtronic, Inc. Public Relations: Kyra Schmitt, 763-526-2490 or

Investor Relations: Jeff Warren, 763-505-2696

Source: Medtronic, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->